Crinetics Pharmaceuticals Inc
NASDAQ:CRNX 1:32:51 PM EDT
| Market Cap (Intraday) | 4.23B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $51.99 |
| 50-Day MA | $51.82 |
| 200-Day MA | $45.88 |
Crinetics Pharmaceuticals Inc Stock, NASDAQ:CRNX
6055 Lusk Boulevard, Building 2, San Diego, California 92121
United States of America
Phone: +1.858.450.6464
Number of Employees: 290
Description
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.